• Andrew M Naidech, Kurt T Kreiter, Nazli Janjua, Noeleen Ostapkovich, Augusto Parra, Christopher Commichau, E Sander Connolly, Stephan A Mayer, and Brian-Fred M Fitzsimmons.
• Department of Neurology, Northwestern University, Chicago, Ill, USA. a-naidech@northwestern.edu
• Stroke. 2005 Mar 1;36(3):583-7.

Background And PurposePhenytoin (PHT) is routinely used for seizure prophylaxis after subarachnoid hemorrhage (SAH), but may adversely affect neurologic and cognitive recovery.MethodsWe studied 527 SAH patients and calculated a "PHT burden" for each by multiplying the average serum level of PHT by the time in days between the first and last measurements, up to a maximum of 14 days from ictus. Functional outcome at 14 days and 3 months was measured with the modified Rankin scale, with poor functional outcome defined as dependence or worse (modified Rankin Scale > or =4). We assessed cognitive outcomes at 14 days and 3 months with the telephone interview for cognitive status.ResultsPHT burden was associated with poor functional outcome at 14 days (OR, 1.5 per quartile; 95% CI, 1.3 to 1.8; P<0.001), although not at 3 months (P=0.09); the effect remained (OR, 1.6 per quartile; 95% CI, 1.2 to 2.1; P<0.001) after correction for admission Glasgow Coma Scale, fever, stroke, age, National Institutes of Health Stroke Scale > or =10, hydrocephalus, clinical vasospasm, and aneurysm rebleeding. Seizure in hospital (OR, 4.1; 95% CI, 1.5 to 11.1; P=0.002) was associated with functional disability in a univariate model only. Higher quartiles of PHT burden were associated with worse telephone interview for cognitive status scores at hospital discharge (P<0.001) and at 3 months (P=0.003).ConclusionsAmong patients treated with PHT, burden of exposure to PHT predicts poor neurologic and cognitive outcome after SAH.

23 keywords...

hide…